Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Atypical pathogens and respiratory tract infections Blasi FEur Respir J 2004[Jul]; 24 (1): 171-81The atypical respiratory pathogens Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila are now recognised as a significant cause of acute respiratory-tract infections, implicated in community-acquired pneumonia, acute exacerbations of chronic bronchitis, asthma, and less frequently, upper respiratory-tract infections. Chronic infection with C. pneumoniae is common among patients with chronic obstructive pulmonary disease and may also play a role in the natural history of asthma, including exacerbations. The lack of a gold standard for diagnosis of these pathogens still handicaps the current understanding of their true prevalence and role in the pathogenesis of acute and chronic respiratory infections. While molecular diagnostic techniques, such as polymerase chain reaction, offer improvements in sensitivity, specificity and rapidity over culture and serology, the need remains for a consistent and reproducible diagnostic technique, available to all microbiology laboratories. Current treatment guidelines for community-acquired pneumonia recognise the importance of atypical respiratory pathogens in its aetiology, for which macrolides are considered suitable first-line agents. The value of atypical coverage in antibiotic therapy for acute exacerbations of chronic bronchitis and exacerbations of asthma is less clear, while there is no evidence to suggest that atypical pathogens should be covered in antibiotic treatment of upper respiratory-tract infections.|Anti-Bacterial Agents/pharmacology[MESH]|Asthma/drug therapy/epidemiology/microbiology[MESH]|Chlamydophila Infections/*diagnosis/drug therapy/epidemiology[MESH]|Drug Resistance, Bacterial[MESH]|Female[MESH]|Humans[MESH]|Incidence[MESH]|Italy/epidemiology[MESH]|Legionnaires' Disease/*diagnosis/drug therapy/epidemiology[MESH]|Male[MESH]|Microbial Sensitivity Tests[MESH]|Pneumonia, Mycoplasma/*diagnosis/drug therapy/epidemiology[MESH]|Prognosis[MESH]|Pulmonary Disease, Chronic Obstructive/drug therapy/epidemiology/microbiology[MESH]|Respiratory Tract Infections/drug therapy/*epidemiology/*microbiology[MESH]|Risk Assessment[MESH]|Severity of Illness Index[MESH]|Survival Rate[MESH]|Treatment Outcome[MESH] |
